Citius Pharmaceuticals, Inc.-Tampa Dinner
Schedule
Wed Jul 07 2021 at 05:30 pm to 07:00 pm
Location
The Capital Grille | Tampa, FL
About this Event
*Due to limited seating, please make sure each individual registers accordingly. You will not be permitted to attend the event without proper registration.
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR)
Wednesday, July 7, 2021
The Capital Grille
2223 North Westshore Blvd
Tampa, FL 33607
Promptly at 5:30 PM
Join Citius Pharmaceuticals, Inc. Chairman Leonard Mazur for this exclusive corporate presentation, followed by a Q & A session moderated by Bear Creek Capital, featuring questions taken from the audience.
We hope you can join our presentation
About Citius Phamaceuticals, Inc.
Citius Pharmaceuticals (NASDAQ: CTXR) is a specialty pharmaceutical company dedicated to the development and commercialization of important new drug products for growing markets. Citius is currently advancing three proprietary product candidates: Mino-Lok®, CITI-002 (halobetasol-lidocaine formulation) and CITI-101 (Mino-Wrap). Citius believes the markets for its products are large and underserved by the current standard of care.
Company Highlights
Citius is committed to developing therapies for unmet medical needs with cost-effective products in high growth categories with low developmental risk.
Mino-Lok product has advanced to Phase 3 clinical studies.
CITI-101 (Mino-Wrap) is a bio-absorbable film impregnated with minocycline and rifampin for reducing acute inflammation and microbial colonization of breast tissue expanders used in breast reconstruction surgeries following mastectomies. More information on this product will be coming soon.
CITI-002 is being developed for symptomatic relief of hemorrhoids. CITI-002 combines the high-potency steroid, halobetasol, with lidocaine.
Citius has an experienced management team with demonstrated success in developing and commercializing novel pharmaceutical products.
In the News
Citius Pharmaceuticals Expands Scientific Advisory Board with Addition of Dr. John Laffey, Expert in Stem Cell and Gene Therapies for ARDS
Citius Pharmaceuticals Achieves Next Interim Analysis Milestone in its Mino-Lok® Phase 3 Trial
Citius Pharmaceuticals to be Added to Russell 2000® Index
Citius Pharmaceuticals to Feature Updated Positive Interim Results of i-MSC Study During Poster Presentation at International Society for Cell and Gene Therapy
Citius Pharmaceuticals, Inc. Announces Appointment of Ilanit Allen as Vice President, Corporate Communications and Investor Relations
Citius Pharmaceuticals, Inc. Reports Second Fiscal Quarter 2021 Financial Results and Provides General Business Update
Citius Pharmaceuticals Reports Strong Clinical Community Engagement During Mino-Lok® Phase 3 Trial-Related Webinar
Citius Pharmaceuticals CEO Myron Holubiak Featured in Benzinga Interview
Citius Pharmaceuticals Announces Closing of $76.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
Citius Pharmaceuticals Issues Shareholder Letter with Corporate Update on Recent Achievements and Anticipated Milestones for 2021
Presentation Format:
5:30 p.m. to 7:00 p.m. – Check In & Networking
6:00 p.m. -7:00 p.m. - Presentation and Dinner
Contact:
Raymond Oliver
CEO, Bear Creek Capital
321-439-2120
Where is it happening?
The Capital Grille, 2223 North Westshore Boulevard, Tampa, United StatesEvent Location & Nearby Stays:
USD 0.00
